Buscar
01/11/2025
CIRTUSARC: A multicenter, open-label phase II trial of cirtuvivint as second-line therapy in selected advanced soft-tissue sarcomas
Martin-Broto, J, Ospina, GM, Garcia, AS, Trufero, JM, Martinez-Garcia, J, Fidalgo, JAP, Morales, CMV, Jurado, JC, Ledesma, P, Grifman, M, Moura, DD, Muñiz, NH. CIRTUSARC: A multicenter, open-label phase II trial of cirtuvivint as second-line therapy in selected advanced soft-tissue sarcomas. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3354. PMID:. IF:65.400(Q1/1D).
01/11/2025
Oncological outcomes for patients with European Association of Urology definitions of BCG failure treated with radical cystectomy
Farré, A, Huguet, J, Basile, G, Diéguez, L, Izquierdo, P, Sánchez, R, Gavrilov, P, Gallioli, A, Faba, OR, Gaya, JM, Palou, J, Breda, A. Oncological outcomes for patients with European Association of Urology definitions of BCG failure treated with radical cystectomy. Actas Urologicas Espanolas. 2025; 49(9)DOI:10.1016/j.acuro.2025.501834. PMID:. IF:1.200(Q3/7D).
01/11/2025
Active Surveillance of Grade Group 2 Prostate Cancer: Oncological Outcomes from a Contemporary European Cohort
Baboudjian, M, Leni, R, Oderda, M, Peyrottes, A, Kesch, C, Al-Nader, M, Uleri, A, Dariane, C, Baud, H, Olivier, J, Rios, AR, Sanguedolce, F, Benard, V, Windisch, O, Valerio, M, Gandaglia, G, Ploussard, G. Active Surveillance of Grade Group 2 Prostate Cancer: Oncological Outcomes from a Contemporary European Cohort. European Urology Oncology. 2025; 8(5)DOI:10.1016/j.euo.2025.01.009. PMID:39965999. IF:9.300(Q1/1D).
01/11/2025
Interobserver reproducibility of a hybrid three-tier grading system of papillary nonmuscle invasive urothelial carcinoma: an international Uropathology study
Downes, MR, Lajkosz, K, Algaba, F, Allory, Y, Amin, MB, Cheng, L, Desai, S, Eckstein, M, Hartmann, A, Lopez-Beltran, A, Mannweiler, S, van Montfoort, ML, Oxley, J, Paner, GP, Samaratunga, H, Shen, S, Warrick, J, Williamson, SR, Wobker, SE, van der Kwast, TH. Interobserver reproducibility of a hybrid three-tier grading system of papillary nonmuscle invasive urothelial carcinoma: an international Uropathology study. HISTOPATHOLOGY. 2025; 87(5)DOI:10.1111/his.15438. PMID:40058790. IF:4.100(Q1/1D).
01/11/2025
Long-Term Effectiveness and Safety of Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa Under Real Clinical Practice Conditions: The Importance of Combined Treatment in Hurley III Patients and Potential Factors Associated with Complete Response
Mansilla-Polo, M, García-Moronta, C, Fernández-Crehuet, P, Garbayo-Salmons, P, Pons-Benavent, M, Aguilar-González, L, Jiménez-Gallo, D, Alcalá-García, R, Martín-Ezquerra, G, Martorell, A, Mahiques-Santos, L, Alfageme-Roldán, F, Escutia-Muñoz, B, Sahuquillo-Torralba, A, Fayos-Gregori, R, Soto-Moreno, A, Sánchez-Gutiérrez, I, Botella-Estrada, R, Vilarrasa, E, Molina-Leyva, A. Long-Term Effectiveness and Safety of Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa Under Real Clinical Practice Conditions: The Importance of Combined Treatment in Hurley III Patients and Potential Factors Associated with Complete Response. Dermatology and Therapy. 2025; 15(11)DOI:10.1007/s13555-025-01521-z. PMID:40866757. IF:4.200(Q1/1D).
01/11/2025
Detection and treatment of early gestational diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
Garcia-Patterson, A, Balsells, M, Solà, I, Corcoy, R. Detection and treatment of early gestational diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 2025; 233(5)DOI:10.1016/j.ajog.2025.04.059. PMID:40320104. IF:8.400(Q1/1D).